array:19 [
  "pii" => "X0211699502027740"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:39"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1664
    "formatos" => array:3 [
      "EPUB" => 194
      "HTML" => 1116
      "PDF" => 354
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027732"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:40"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 7906
      "formatos" => array:3 [
        "EPUB" => 194
        "HTML" => 6414
        "PDF" => 1298
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Fisiopatología del daño renal asociado a proteinuria. Estrategias terapéuticas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "40"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M. PRAGA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "M. PRAGA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027732?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027732/v0_201502091327/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027759"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:37-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2820
      "formatos" => array:3 [
        "EPUB" => 182
        "HTML" => 2236
        "PDF" => 402
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Implicaciones clínicas y terapéuticas de la hipertrofia ventricular izquierda en la hipertensión"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "37"
          "paginaFinal" => "38"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. BARRIOS"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. BARRIOS"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027759?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027759/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Prevention of chronic renal disease progression"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "39"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "F. LOCATELLI , L. DE VECCHIO"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "F. LOCATELLI , L. DE VECCHIO"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Prevention of chronic renal disease progression F. Locatelli and L. del Vecchio Department of Nephrology and Dialysis. Ospedale A. Manzoni, Lecco. Italy. Preventing renal disease from progressing to endstage renal failure (ESRF) is not only a medical challenge, but also a growing social and economic problem in many countries. The identification and correction of physiological and metabolic hanges that may contribute towards progressive renal deterioration is thus crucial. Proteinuria and hypertension are the major factors contributing to the progression of chronic renal disease and effective antihypertensive therapy is currently the single most important treatment i chronic renal insufficiency (CRI) pateints&#59; this also in the perspective that lowering blood pressure in the major determinant of proteinuria reduction. Some hypertensive agents may be capable of reducing CRI progression not only because of their antihypertensive and antiproteinuric effects, but also because they may halt some of the pathogenetic mechanisms involved in glomerular and tubulo-interstitial renal damage. There seems to be a clear difference in the antiproteinuric capacity of the different classes of antihypertensive drugs, with ACE inhibitors, angiotensin II receptor antagonists (AT1RA) and non-dihydropyridine calcium channel blockers (CCBS) having the greatest capacity to reduce urinary protein excretion. However, it seems that, after a significant decrease in blood pressure, the antiproteinuric effect of all of the antihypertensive drugs became nearly the same, although this should be tested in randomised, controlled trials. According to the results of large trials, ACE inhibitors also significantly reduce the rate of loss of renal function in diabetic and non-diabetic chronic renal diseases&#59; this effect is greatest in patients with substantial proteinuria at baseline. It is worth noting that the HOPE study strongly supported the use of ACE inhibitors as preventive agents for patients at high risk of cardiovascular events (such as CRI patients). AT1RAs have recently been proved of benefit in type 2 diabetic nephropathy. The possible renoprotective effect of CCBs is still controversial. The possibility that combination treatments with some classes of antihypertensive drugs (i.e. ACE inhibitors, CCBs, AT1RAs) may have additive or even synergistic renoprotective effects other than blood presure control is extremely fascinating, also consi- dering that multidrug antihypertensive regimens are required to obtain the present blood pressure target in the majority of patients with CRI&#59; however, this has still to be proved. Dyslipidemia is common in patients with chronic renal disease, especially in those with more severe CRI or the nephrotic syndrome. Since the first observation that lipids accumulate within scarred kidneys, it has been suggested that dyslipoproteinemia contributes towards the progression of glomerular and tubular lesions, which leads to a subsequent deterioration in renal function. While awaiting for the results of ongoing trials about the possible role of statins in the prevention of CRI progression, lipid-lowering therapy can not still be recommended for renoprotection. However, recommendations should also be based on the well established cardiovascular risk associated with hyperlipidaemia. In addition, statins may influence important intracellular pathways that are involved in inflammatory and fibrogenic responses leading to vascular disease. This is likely to be all the more relevant in patients with ESRF, whose cardiovascular morbidity and mortality is considerably increased. Dietary protein restriction is effective in slowing down the rate of CRI progression, but this effect marginally delay the time when ESRF is reached. For this reason, very-low-protein intakes or vegetarian regimens should be considered only in highly motivated patients, without forgetting that the risk of malnutrition. The calcium and phosphorus metabolism seems not to play a major role in the progression of renal injury, at least in the early phase&#59; further studies are needed to elucidate whether lipid abnormalities have a casual role in CRI progression or they are merely a consequence of metabolic derangements. However, given that hyperphosphoremia, hyperparathyroidism and dyslipidemia may contribute to the development of cardiovascular disease in CRI patients, great attention has to be paid to the treatment of these conditions. Finally, it is important to stress that general medical care is a very strong determinant of patient outcome in the conservative phase of CRI treatment. For this reason intervention has to be tailored to each patient in order of not only preserving residual renal function, but also guaranteeing patient well-being 39 "
    "pdfFichero" => "P7-E193-S140-A3694.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/P7-E193-S140-A3694.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027740?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Prevention of chronic renal disease progression
F. LOCATELLI , L. DE VECCHIO
Leído
4339
Veces
se ha leído el artículo
1731
Total PDF
2608
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699502027740"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:39"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1664
    "formatos" => array:3 [
      "EPUB" => 194
      "HTML" => 1116
      "PDF" => 354
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027732"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:40"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 7906
      "formatos" => array:3 [
        "EPUB" => 194
        "HTML" => 6414
        "PDF" => 1298
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Fisiopatología del daño renal asociado a proteinuria. Estrategias terapéuticas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "40"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M. PRAGA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "M. PRAGA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027732?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027732/v0_201502091327/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027759"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:37-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2820
      "formatos" => array:3 [
        "EPUB" => 182
        "HTML" => 2236
        "PDF" => 402
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Implicaciones clínicas y terapéuticas de la hipertrofia ventricular izquierda en la hipertensión"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "37"
          "paginaFinal" => "38"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "V. BARRIOS"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "V. BARRIOS"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027759?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027759/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Prevention of chronic renal disease progression"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "39"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "F. LOCATELLI , L. DE VECCHIO"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "F. LOCATELLI , L. DE VECCHIO"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Prevention of chronic renal disease progression F. Locatelli and L. del Vecchio Department of Nephrology and Dialysis. Ospedale A. Manzoni, Lecco. Italy. Preventing renal disease from progressing to endstage renal failure (ESRF) is not only a medical challenge, but also a growing social and economic problem in many countries. The identification and correction of physiological and metabolic hanges that may contribute towards progressive renal deterioration is thus crucial. Proteinuria and hypertension are the major factors contributing to the progression of chronic renal disease and effective antihypertensive therapy is currently the single most important treatment i chronic renal insufficiency (CRI) pateints&#59; this also in the perspective that lowering blood pressure in the major determinant of proteinuria reduction. Some hypertensive agents may be capable of reducing CRI progression not only because of their antihypertensive and antiproteinuric effects, but also because they may halt some of the pathogenetic mechanisms involved in glomerular and tubulo-interstitial renal damage. There seems to be a clear difference in the antiproteinuric capacity of the different classes of antihypertensive drugs, with ACE inhibitors, angiotensin II receptor antagonists (AT1RA) and non-dihydropyridine calcium channel blockers (CCBS) having the greatest capacity to reduce urinary protein excretion. However, it seems that, after a significant decrease in blood pressure, the antiproteinuric effect of all of the antihypertensive drugs became nearly the same, although this should be tested in randomised, controlled trials. According to the results of large trials, ACE inhibitors also significantly reduce the rate of loss of renal function in diabetic and non-diabetic chronic renal diseases&#59; this effect is greatest in patients with substantial proteinuria at baseline. It is worth noting that the HOPE study strongly supported the use of ACE inhibitors as preventive agents for patients at high risk of cardiovascular events (such as CRI patients). AT1RAs have recently been proved of benefit in type 2 diabetic nephropathy. The possible renoprotective effect of CCBs is still controversial. The possibility that combination treatments with some classes of antihypertensive drugs (i.e. ACE inhibitors, CCBs, AT1RAs) may have additive or even synergistic renoprotective effects other than blood presure control is extremely fascinating, also consi- dering that multidrug antihypertensive regimens are required to obtain the present blood pressure target in the majority of patients with CRI&#59; however, this has still to be proved. Dyslipidemia is common in patients with chronic renal disease, especially in those with more severe CRI or the nephrotic syndrome. Since the first observation that lipids accumulate within scarred kidneys, it has been suggested that dyslipoproteinemia contributes towards the progression of glomerular and tubular lesions, which leads to a subsequent deterioration in renal function. While awaiting for the results of ongoing trials about the possible role of statins in the prevention of CRI progression, lipid-lowering therapy can not still be recommended for renoprotection. However, recommendations should also be based on the well established cardiovascular risk associated with hyperlipidaemia. In addition, statins may influence important intracellular pathways that are involved in inflammatory and fibrogenic responses leading to vascular disease. This is likely to be all the more relevant in patients with ESRF, whose cardiovascular morbidity and mortality is considerably increased. Dietary protein restriction is effective in slowing down the rate of CRI progression, but this effect marginally delay the time when ESRF is reached. For this reason, very-low-protein intakes or vegetarian regimens should be considered only in highly motivated patients, without forgetting that the risk of malnutrition. The calcium and phosphorus metabolism seems not to play a major role in the progression of renal injury, at least in the early phase&#59; further studies are needed to elucidate whether lipid abnormalities have a casual role in CRI progression or they are merely a consequence of metabolic derangements. However, given that hyperphosphoremia, hyperparathyroidism and dyslipidemia may contribute to the development of cardiovascular disease in CRI patients, great attention has to be paid to the treatment of these conditions. Finally, it is important to stress that general medical care is a very strong determinant of patient outcome in the conservative phase of CRI treatment. For this reason intervention has to be tailored to each patient in order of not only preserving residual renal function, but also guaranteeing patient well-being 39 "
    "pdfFichero" => "P7-E193-S140-A3694.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027740/v0_201502091327/en/P7-E193-S140-A3694.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027740?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 4 6 10
2024 Octubre 34 40 74
2024 Septiembre 24 23 47
2024 Agosto 48 60 108
2024 Julio 32 27 59
2024 Junio 41 36 77
2024 Mayo 58 25 83
2024 Abril 35 36 71
2024 Marzo 19 22 41
2024 Febrero 31 38 69
2024 Enero 27 22 49
2023 Diciembre 21 20 41
2023 Noviembre 31 31 62
2023 Octubre 25 47 72
2023 Septiembre 20 26 46
2023 Agosto 22 21 43
2023 Julio 28 37 65
2023 Junio 26 12 38
2023 Mayo 31 24 55
2023 Abril 10 21 31
2023 Marzo 33 19 52
2023 Febrero 19 16 35
2023 Enero 28 20 48
2022 Diciembre 30 21 51
2022 Noviembre 17 19 36
2022 Octubre 24 41 65
2022 Septiembre 25 29 54
2022 Agosto 30 30 60
2022 Julio 23 41 64
2022 Junio 20 18 38
2022 Mayo 30 38 68
2022 Abril 27 27 54
2022 Marzo 40 33 73
2022 Febrero 21 30 51
2022 Enero 25 31 56
2021 Diciembre 32 33 65
2021 Noviembre 22 33 55
2021 Octubre 23 33 56
2021 Septiembre 24 28 52
2021 Agosto 21 24 45
2021 Julio 30 31 61
2021 Junio 20 16 36
2021 Mayo 26 24 50
2021 Abril 40 30 70
2021 Marzo 34 7 41
2021 Febrero 24 14 38
2021 Enero 13 13 26
2020 Diciembre 14 14 28
2020 Noviembre 18 8 26
2020 Octubre 20 11 31
2020 Septiembre 22 5 27
2020 Agosto 24 8 32
2020 Julio 13 6 19
2020 Junio 18 13 31
2020 Mayo 23 13 36
2020 Abril 24 11 35
2020 Marzo 35 10 45
2020 Febrero 25 18 43
2020 Enero 27 17 44
2019 Diciembre 24 9 33
2019 Noviembre 19 11 30
2019 Octubre 8 6 14
2019 Septiembre 13 8 21
2019 Agosto 6 7 13
2019 Julio 17 13 30
2019 Junio 24 9 33
2019 Mayo 5 11 16
2019 Abril 30 29 59
2019 Marzo 12 11 23
2019 Febrero 5 8 13
2019 Enero 11 9 20
2018 Diciembre 23 20 43
2018 Noviembre 24 5 29
2018 Octubre 20 9 29
2018 Septiembre 21 6 27
2018 Agosto 15 10 25
2018 Julio 11 6 17
2018 Junio 16 8 24
2018 Mayo 15 5 20
2018 Abril 15 3 18
2018 Marzo 12 5 17
2018 Febrero 7 1 8
2018 Enero 9 4 13
2017 Diciembre 10 5 15
2017 Noviembre 8 2 10
2017 Octubre 12 6 18
2017 Septiembre 9 10 19
2017 Agosto 15 23 38
2017 Julio 20 7 27
2017 Junio 16 4 20
2017 Mayo 17 4 21
2017 Abril 13 1 14
2017 Marzo 8 27 35
2017 Febrero 5 0 5
2017 Enero 7 2 9
2016 Diciembre 16 7 23
2016 Noviembre 24 5 29
2016 Octubre 25 4 29
2016 Septiembre 23 4 27
2016 Agosto 64 0 64
2016 Julio 41 0 41
2016 Junio 40 0 40
2016 Mayo 65 0 65
2016 Abril 31 0 31
2016 Marzo 29 0 29
2016 Febrero 36 0 36
2016 Enero 9 0 9
2015 Diciembre 31 0 31
2015 Noviembre 28 0 28
2015 Octubre 18 0 18
2015 Septiembre 22 0 22
2015 Agosto 28 0 28
2015 Julio 27 0 27
2015 Junio 2 0 2
2015 Mayo 15 0 15
2015 Febrero 1 0 1
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?